{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:47Z","timestamp":1787070947867,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy and safety of sequential treatment of continuous transcatheter hepatic artery infusion chemotherapy (HAIC) with systemic capecitabine monotherapy and camrelizumab for treating unresectable hilar cholangiocarcinoma (HCCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study retrospectively analyzed patients with unresectable HCCA admitted to Linyi Cancer Hospital in Shandong Province from October 2019 to December 2021. All enrolled patients were treated with HAIC (mFOLFOX7) + camrelizumab for 2\u20136 cycles and administered systemic therapy with capecitabine and camrelizumab. The objective response rate (ORR), disease control rate (DCR), and adverse reactions of patients were assessed. The Kaplan\u2013Meier method was used to describe overall survival (OS), and univariate and multivariate Cox regression models were utilized to analyze the influencing factors of OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This study included 34 patients, ORR was 61.76% (21\/34), and DCR was 97.06% (33\/34) after two HAIC cycles. The median follow-up time was 17.5 months, with an average of 18.32 \u00b1 8.06 months, and the median OS was 20.0 months. HAIC-related adverse reactions included mainly gastrointestinal symptoms and hematological toxicity caused by chemotherapy drugs, all of which were grades 1\u20132. Further, adverse events for camrelizumab treatment included fatigue, skin rash, and hypothyroidism, all of which were grade &lt;3. Cox regression analysis revealed that the periductal infiltrating type of growth pattern indicated a worse OS, whereas more HAIC cycles (5 ~ 6) were a protective factor for OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HAIC sequentially combined with systemic capecitabine chemotherapy and a programmed death-1 inhibitor displayed favorable effects for unresectable HCCA, with controllable adverse reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1549_23","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:02:16Z","timestamp":1714496536000},"page":"578-583","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Hepatic artery infusion chemotherapy with systemic capecitabine and camrelizumab for treating unresectable hilar cholangiocarcinoma: An initial investigation of efficacy and safety"],"prefix":"10.4103","volume":"20","author":[{"given":"Long","family":"Li","sequence":"first","affiliation":[{"name":"Qingdao Medical College of Qingdao University, No. 1, Ningde Road, Qingdao 266073, Shandong Province, China"},{"name":"Interventional Medicine Center, Linyi Cancer Hospital, Intersection of Zhicheng Road and Zhongsheng Street, Linyi 276034, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[{"name":"Interventional Medicine Center, Linyi Cancer Hospital, Intersection of Zhicheng Road and Zhongsheng Street, Linyi 276034, Shandong Province, China"},{"name":"Graduate School of Dalian Medical University, No. 9 Western Section, Lvshun South Street, Lvshun District, Dalian, 116044, Liaoning Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingdong","family":"Wang","sequence":"additional","affiliation":[{"name":"Interventional Medicine Center, Linyi Cancer Hospital, Intersection of Zhicheng Road and Zhongsheng Street, Linyi 276034, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Qingdao Medical College of Qingdao University, No. 1, Ningde Road, Qingdao 266073, Shandong Province, China"},{"name":"Interventional Medicine Center, Affiliated Hospital of Qingdao University, No. 369, Shanghai Road, Pingdu City, Qingdao 266073, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Yu","sequence":"additional","affiliation":[{"name":"Interventional Medicine Center, Linyi Cancer Hospital, Intersection of Zhicheng Road and Zhongsheng Street, Linyi 276034, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4103\/jcrt.JCRT_637_19","article-title":"Analysis of treatment methods and prognostic factors in 354 cases of hilar cholangiocarcinoma:A cohort study","volume":"16","author":"Sun","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J Hepatol"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/jcrt.JCRT_804_19","article-title":"A newly designed biliary brachytherapy drainage catheter for patients with malignant biliary obstruction:A pilot study","volume":"16","author":"Jiao","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/jcrt.jcrt_2038_22","article-title":"Prognostic effects of different malignant obstructive jaundice sites on percutaneous biliary intervention:A retrospective controlled study","volume":"19","author":"Xu","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s00268-018-4530-0","article-title":"Defining early recurrence of Hilar cholangiocarcinoma after curative-intent surgery:A multi-institutional study from the US Extrahepatic Biliary Malignancy Consortium","volume":"42","author":"Zhang","year":"2018","journal-title":"World J Surg"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"273","author":"Cambridge","year":"2021","journal-title":"Ann Surg. Ann Surg"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.21037\/apm-22-676","article-title":"The efficacy and safety of biliary stenting alone versus stenting combined with iodine-125 seed strand implantation for the treatment of cholangiocarcinoma with malignant obstructive jaundice:A prospective, nonrandomized, controlled clinical study","volume":"11","author":"Luo","year":"2022","journal-title":"Ann Palliat Med"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10620-017-4899-x","article-title":"Efficacy of 125I versus Non-125I combined with transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma with obstructive jaundice","volume":"63","author":"Li","year":"2018","journal-title":"Dig Dis Sci"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4103\/jcrt.JCRT_563_20","article-title":"The clinical efficacy of computed tomography-guided 125I particle implantation combined with arterial infusion chemotherapy in the treatment of pancreatic cancer","volume":"17","author":"Yang","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1245\/s10434-022-11439-x","article-title":"Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma:A systematic review and meta-analysis","volume":"29","author":"Holster","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4251\/wjgo.v11.i6.489","article-title":"Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma","volume":"11","author":"Zheng","year":"2019","journal-title":"World J Gastrointest Oncol"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma:A randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/jcrt.jcrt_1078_21","article-title":"Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk","volume":"18","author":"Wu","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","article-title":"Systemic therapies for intrahepatic cholangiocarcinoma","volume":"72","author":"Kelley","year":"2020","journal-title":"J Hepatol"},{"key":"R16-20241021","first-page":"828","article-title":"Expert consensus on diagnosis and treatment of CSCO biliary systerm tumors (2019 edition)","volume":"24","year":"2019","journal-title":"J Clin Oncol"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer:Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer:A non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R19-20241021","first-page":"3455","article-title":"Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer:A multicenter retrospective study","volume":"12","author":"Zhang","year":"2022","journal-title":"Am J Cancer Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1549_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:25Z","timestamp":1787067565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1549_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1549_23","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2023-07-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}